A schematic presentation of deregulated pathways involved in BRAFi-resistant melanoma cells and a hypothetical model for anti-WNT5A therapy that would contravene BRAFi-resistance is illustrated in Figure 2. This evidence concerns the gene WNT5A and melanoma.